Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Chromatin Accessibility Identifies Regulatory Elements Predictive of Oncogene Expression in Multiple Myeloma

Benjamin G Barwick, PhD, Vikas A. Gupta, MD PhD, Shannon M Matulis, PhD, Jonathan C Patton, B.S., Doris R Powell, MA, Yanyan Gu, MD PhD, David L. Jaye, MD, Karen N Conneely, PhD, Yin C Lin, PhD, Craig C Hofmeister, MDMPH, Ajay Nooka, MDMPH, Jonathan J Keats, PhD, Sagar Lonial, MD FACP, Paula M Vertino, PhD, Larry H. Boise, PhD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-140717

Published: 2020

Journal Articles

Increased DNA Repair Gene Expression Correlates with MYC Expression and Inferior Progression-Free Survival in Multiple Myeloma Patients

Karen Sweiss, PharmD, Benjamin G Barwick, PhD, Gregory Sampang Calip, PharmD,MPH,PhD, Damiano Rondelli, MD, Craig C Hofmeister, MDMPH, Pritesh Patel, MB, ChB

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-143422

Published: 2020

Journal Articles

Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-142110

Published: 2020

Journal Articles

Role of clonoSEQ ® , a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma

Ajay Nooka, MDMPH, Kyle Bradley, MD MS, Nisha Joseph, MD, Craig C Hofmeister, MDMPH, Madhav V. Dhodapkar, MD, Larry H. Boise, PhD, Sagar Lonial, MD FACP, Shiyong Li, MD PhD, Jonathan L. Kaufman, MD

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-143093

Published: 2020

Journal Articles

Real World Experience and Patient Satisfaction Surrounding the Implementation of Daratumumab and Hyaluronidase-Fihj in a Large, Academic Medical Center

Kathryn T. Maples, PharmD, Erich Brechtelsbauer, PharmD, Julia Pendexter, PharmD, Jonathan L. Kaufman, MD, Nisha Joseph, MD, Leonard Heffner, MD, Craig C Hofmeister, MDMPH, Madhav V. Dhodapkar, MD, Sagar Lonial, MD FACP, Ajay Nooka, MDMPH

Blood (2020) 136 (Supplement 1): 9.

https://doi.org/10.1182/blood-2020-142995

Published: 2020

Journal Articles

Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma

Ada Dona', PhD, Domenico Viola, Enrico Caserta, PhD, Francesca Besi, PhD, James F Sanchez, PhD, Guido Marcucci, MD, Jonathan J Keats, PhD, Amrita Y. Krishnan, MD, Matt Coffey, PhD, Douglas W. Sborov, MDMSc, Gerard Nuovo, MD, Craig C Hofmeister, MDMPH, Flavia Pichiorri, PhD

Blood (2019) 134 (Supplement_1): 1816.

https://doi.org/10.1182/blood-2019-128740

Published: 2019

Journal Articles

Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

Ravi Vij, MBBS, Thomas G. Martin, III, MD, Nitya Nathwani, MD, Mark A. Fiala, BS, Feng Gao, PhD, Abhinav Deol, MD, Francis K. Buadi, MB, CHB, Jonathan L. Kaufman, MD, Craig C Hofmeister, MDMPH, Tara K. Gregory, MD, Jesus G. Berdeja, MD, Ajai Chari, MD, Ashley E. Rosko, MD

Blood (2019) 134 (Supplement_1): 602.

https://doi.org/10.1182/blood-2019-130644

Published: 2019

Journal Articles

Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

Blood (2019) 134 (Supplement_1): 4525.

https://doi.org/10.1182/blood-2019-129488

Published: 2019

Journal Articles

The Role of Proteasome Activator PA28α in Multiple Myeloma

Yanyan Gu, MD PhD, Benjamin G Barwick, PhD, Mala Shanmugam, PhD, Craig C Hofmeister, MDMPH, Jonathan L. Kaufman, MD, Ajay K Nooka, MDMPH, Vikas A. Gupta, MD PhD, Madhav V Dhodapkar, MBBS, Lawrence H. Boise, PhD, Sagar Lonial

Blood (2019) 134 (Supplement_1): 5499.

https://doi.org/10.1182/blood-2019-128216

Published: 2019

Journal Articles

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Leon Bernal-Mizrachi, MD, Ajay K Nooka, MDMPH, Leonard Heffner, MD, Craig E. Cole, MD, J Christine Ye, MDMSc, Ravi Vij, MBBS, Craig C Hofmeister, MDMPH, John Rushton, PhD, Zhengjia Chen, PhD, Zhao Chang, PhD, Munevver Cinar, MD, Daniel Auclair, Sagar Lonial, Jonathan L. Kaufman, MD

Blood (2019) 134 (Supplement_1): 3188.

https://doi.org/10.1182/blood-2019-131223

Published: 2019

Journal Articles

Oncolytics Virus Replication Using Pelareorep (Reolysin) and Carfilzomib in Relapsed Myeloma Patients Increases PD-L1 Expression with Clinical Responses

Craig C Hofmeister, MDMPH, Douglas W. Sborov, MD MS, Domenico Viola, Ada Dona, Gerald J Nuovo, PhD, Don M. Benson, Jr., MD PhD, Sagar Lonial, MD, Jonathan L Kaufman, MD, Ajay K Nooka, MD MPH, Leonard Heffner, MD, Madhav V Dhodapkar, MD, Flavia Pichiorri, PhD

Blood (2018) 132 (Supplement 1): 2655.

https://doi.org/10.1182/blood-2018-99-113500

Published: 2018

Journal Articles

Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi-Center Phase II Trial

Ravi Vij, MBBS, Nitya Nathwani, MD, Thomas G. Martin, III, MD, Mark A. Fiala, BS, Abhinav Deol, MD, Francis K. Buadi, MB, CHB, Jonathan L Kaufman, MD, Craig C Hofmeister, MDMPH, Tara Gregory, MD, Jesus G. Berdeja, MD, Ajai Chari, MD, Ashley E. Rosko, MD

Blood (2018) 132 (Supplement 1): 123.

https://doi.org/10.1182/blood-2018-99-109920

Published: 2018

Journal Articles

Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)

Blood (2018) 132 (Supplement 1): 1994.

https://doi.org/10.1182/blood-2018-99-113467

Published: 2018

Journal Articles

B-Cell Lymphoma Patients Have a 10% Risk of Shingles, 7% in Cutaneous T-Cell Lymphoma

Syed Basir Hussaini, BS, Jacqueline Chu, BA, Nita Williams, BS, Nidhi Sharma, PhD, Don M Benson, Jr., MD PhD, Ashley E Rosko, MD, Yvonne A Efebera, MD, Craig C Hofmeister, MDMPH

Blood (2017) 130 (Supplement 1): 3356.

https://doi.org/10.1182/blood.V130.Suppl_1.3356.3356

Published: 2017

Journal Articles

Response Rates, Non-Relapse Mortality, and Financial Implications of Transplant-Associated Thrombotic Microangiopathy Treated with Eculizumab

Blood (2017) 130 (Supplement 1): 1932.

https://doi.org/10.1182/blood.V130.Suppl_1.1932.1932

Published: 2017

Journal Articles

Ninety-Minute Daratumumab Infusion Is Safe in Multiple Myeloma

Hallie Barr, PharmD, Jessica Dempsey, PharmD, BCOP, Allyson Waller, PharmD, Ying Huang, MD, Nita Williams, BS, Nidhi Sharma, PhD, Don M Benson, Jr., MD PhD, Ashley E Rosko, MD, Yvonne A Efebera, MD, Craig C Hofmeister, MDMPH

Blood (2017) 130 (Supplement 1): 1889.

https://doi.org/10.1182/blood.V130.Suppl_1.1889.1889

Published: 2017

Journal Articles

Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies

Meletios A. Dimopoulos, Jacob Laubach, MD, Maria Asuncion Echeveste Gutierrez, Norbert Grząśko, Craig C Hofmeister, MDMPH, Jesus F. San Miguel, MD, Shaji K Kumar, MD, Vickie Lu, PhD, Zhaoyang Teng, PhD, Guohui Liu, PhD, Catriona Byrne, RN, Deborah Berg, RN, MSN, Richard Labotka, MD MS, Helgi van de Velde, MD PhD, Paul G Richardson, MD

Blood (2017) 130 (Supplement 1): 902.

https://doi.org/10.1182/blood.V130.Suppl_1.902.902

Published: 2017

Journal Articles

Utility of Clinical-Grade Sequencing of Relapsed Multiple Myeloma Patients; Interim Analysis of the Multiple Myeloma Research Foundation (MMRF) Molecular Profiling Protocol

Blood (2017) 130 (Supplement 1): 395.

https://doi.org/10.1182/blood.V130.Suppl_1.395.395

Published: 2017

Journal Articles

Transplant Associated Thrombotic Microangiopathy (TA-TMA) Commonly Occurs after Steroid-Refractory or Dependent Gastrointestinal (GI) Graft Versus Host Disease (GVHD) and Contributes to Post-Transplant Morbidity

Blood (2017) 130 (Supplement 1): 4483.

https://doi.org/10.1182/blood.V130.Suppl_1.4483.4483

Published: 2017

Journal Articles

Shingles Occurs in Only 0.5% of Myeloma Patients on Any Dose of Antiviral Prophylaxis

Jacqueline Chu, BA, Syed Basir Hussaini, BS, Nidhi Sharma, PhD, Nita Williams, BS, Don M Benson, Jr., MD PhD, Ashley E Rosko, MD, Yvonne A Efebera, MD, Craig C Hofmeister, MDMPH

Blood (2017) 130 (Supplement 1): 4645.

https://doi.org/10.1182/blood.V130.Suppl_1.4645.4645

Published: 2017

NARROW

Chromatin Accessibility Identifies Regulatory Elements Predictive of Oncogene Expression in Multiple Myeloma

Increased DNA Repair Gene Expression Correlates with MYC Expression and Inferior Progression-Free Survival in Multiple Myeloma Patients

Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era

Role of clonoSEQ ® , a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma

Real World Experience and Patient Satisfaction Surrounding the Implementation of Daratumumab and Hyaluronidase-Fihj in a Large, Academic Medical Center

Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma

Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

The Role of Proteasome Activator PA28α in Multiple Myeloma

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Oncolytics Virus Replication Using Pelareorep (Reolysin) and Carfilzomib in Relapsed Myeloma Patients Increases PD-L1 Expression with Clinical Responses

Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi-Center Phase II Trial

Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)

B-Cell Lymphoma Patients Have a 10% Risk of Shingles, 7% in Cutaneous T-Cell Lymphoma

Response Rates, Non-Relapse Mortality, and Financial Implications of Transplant-Associated Thrombotic Microangiopathy Treated with Eculizumab

Ninety-Minute Daratumumab Infusion Is Safe in Multiple Myeloma

Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies

Utility of Clinical-Grade Sequencing of Relapsed Multiple Myeloma Patients; Interim Analysis of the Multiple Myeloma Research Foundation (MMRF) Molecular Profiling Protocol

Transplant Associated Thrombotic Microangiopathy (TA-TMA) Commonly Occurs after Steroid-Refractory or Dependent Gastrointestinal (GI) Graft Versus Host Disease (GVHD) and Contributes to Post-Transplant Morbidity

Shingles Occurs in Only 0.5% of Myeloma Patients on Any Dose of Antiviral Prophylaxis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only